GTx Announces Conference Call and Webcast to Discuss Ostarine Phase II Clinical Trial Results and an Update on GTx SARM Program
Thursday December 7, 4:54 pm ET
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI - News), the Men's Health Biotech Company, announced that it will host a conference call and webcast tomorrow, December 8, 2006, at 9:00 a.m. Eastern Time to discuss results of the ostarine Phase II proof of concept clinical trial and to provide an update on its SARM program. GTx will issue a press release announcing the clinical trial results and SARM program update before the call.
To listen to the conference call, please dial:
866-202-4367 from the United States and Canada or
617-213-8845 (International)
The access code for the call is 32056343.
A playback of the call will be available beginning tomorrow at 11:00 a.m. Eastern Time through December 22, and may be accessed by dialing:
888-286-8010 from the United States and Canada or
617-801-6888 (International)
The reservation number for the replay is 89704161. |
